Company / Operating Cash Flow
Adaptimmune Therapeutics PLC Operating Cash Flow History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$73.2M
FY2024
5-year range
-$141.8M / $10.7M
FY2020-FY2024
Trend
+48.0%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 9 years, ranging from -$142M in FY2022 to $11M in FY2021.
Based on SEC 10-K filings.
-$73M in FY2024.
Improved from -$142M to -$73M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating cash flow increased 48.0% year-over-year.
- Peak operating cash flow was recorded in FY2021.
- Lowest operating cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -3.53 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$73.2M | +48.0% |
| FY2023 | -$140.9M | +0.6% |
| FY2022 | -$141.8M | -1421.4% |
| FY2021 | $10.7M | +120.0% |
| FY2020 | -$53.6M | +52.4% |
| FY2019 | -$112.5M | -7.8% |
| FY2018 | -$104.4M | -92.2% |
| FY2017 | -$54.3M | -12.8% |
| FY2016 | -$48.2M | - |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026